



**George H. Scherr, Ph.D.  
33 Monee Road  
Park Forest, Illinois 60466  
U.S.A.**

Phone: (708)747-3717  
Fax: (708)747-3657  
E-mail: [jir@interaccess.com](mailto:jir@interaccess.com)

7  
VER  
8-26 J

**Amended Declaration and Oath for Patent Application  
Declaration claiming small entity status (37 CFR 1.9 (f) and 1.27 (b))**

This amended declaration and oath are appended hereto replace the declaration and oath filed with the instant Application Number 09/818,928 on March 28, 2001.

As the below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9 (c) for purposes of paying reduced fees under section 41 (a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled CELLULOSIC FOAM COMPOSITIONS described in the specification filed herewith.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9 (c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9 (d) or a nonprofit organization under 37 CFR 1.9 (e).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

As the below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled.

#### CELLULOSIC FOAM COMPOSITIONS

The specification of which is attached hereto.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I do not claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) None

Priority Claimed  
NO

I hereby declare that I have prepared, reviewed, and understand the contents of the specification and claims of the application number 09/818,928 as filed with the U.S. Patent Office on March 28, 2001, and that I have prepared, reviewed, and understand the amended claims numbers 78-107 as submitted to the U.S. Patent Office.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

George H. Scherr, Ph.D.

Full name of sole inventor

*George H. Scherr*

*August 8, 2003*

Inventor's signature

Date

33 Monee Road, Park Forest, IL 60466

Residence

United States of America

Citizenship

P.O. Box 134, Park Forest, IL 60466

Post Office Address


Phone: (708) 747-3717

Fax: (708) 747-3657

E-mail: jir@interaccess.com

On August 8, 2003, BEFORE ME personally came George H. Scherr to me known, and known to me to be the individual who executed the foregoing DECLARATION, and duly acknowledged to me that he executed the same.

*Jean M. Jacobs*  
\_\_\_\_\_  
Notary signature



CURRICULUM VITAE: GEORGE H. SCHERR, Ph.D.

Education:

1937-1941  
Queens College, Long Island, N. Y.  
Major-Biology; Minor-Chemistry  
B.S., June 1941

1946  
Princeton University (Extension)  
Advanced Organic Chemistry; graduate credit

1948-1951  
University of Kentucky, Lexington  
Major-Bacteriology; Minor-Cytogenetics  
M.S., August, 1949  
Ph.D., July 1951

Employment:

1941-1942  
New York City Dept. of Health, Social Hygiene Clinic  
125 Worth St., N.Y.C., N.Y.  
Medical technician and bacteriologist

1942-1943  
U.S. Civil Service Commission, AAFTTC, Sioux Falls, S.D.  
Senior Instructor, p-2

1943-1944; 1945-1947  
American Cyanamid Co., Calco Chemical Division, Bound  
Brook, N. J.  
Chemist, process development of drugs, dyes, and dye  
intermediates.

1944-1945  
In service. Animal research division of the Biological  
Warfare Service, Camp Detrick, Md.

1948  
Nuodex Products Co., Elizabeth, N. J.  
Chemist, naphthenic acid products and fungicides

1951-1954  
Department of Microbiology, School of Medicine, The  
Creighton University, Omaha, Nebraska, Ass't Professor

1954-1959  
Dept. of Bacteriology, The University of Illinois,  
College of Medicine, Chicago, Ill.  
Assoc. Professor - Tenured

1959 - 1969  
Director of Research, Colab Laboratories, Inc.  
1526 Halsted St., Chicago IL 60411

1969 - 1971  
Administrative Research Director, Division of Diagnostics,  
Wilson Pharmaceutical Co., 3 Science Rd., Glenwood, IL 60425

1971 - 1982  
President and Director of Research, Technam, Inc.  
2405 Bond Street, Park Forest South, IL 60466

1973 - 1984  
Adjunct Professor, Allied Health Sciences Education  
Governors State University, Park Forest South, IL 60466

1978 - 1981  
Publisher  
Pathotox Publishers, Inc.  
2405 Bond Street, Park Forest, IL 60466

1981-1986  
President and Director, Testhrix, Inc.  
Box 134, Park Forest, IL 60466

1982 - 1984  
Consultant Immunologist, Argonne National Laboratory  
9700 S. Cass Avenue, Argonne, IL 60439

1990 - 1991  
Director of Research  
Shepherd Medical Corp.  
15 Roth Street  
Alexandria, VA 22303

1990 - 1991  
Consulting Toxicologist  
Illinois State Racehorse Commission  
Chicago, IL

1975 - Present  
Executive Research Director, American Drug Research Institute (ADRI)  
232 Main Street, Park Forest, IL 60466

1981 - Present  
Director, CHEM-Orbital  
Box 134, Park Forest, IL 60466

GEORGE H. SCHERR

Papers and Publications

\*The induction of bacteriophage-resistant mutation of Escherichia coli by carcinogenic agents

Soc. of Amer. Bacteriologists, Abstracts of Papers, 1949  
With R. H. Weaver

The induction of bacteriophage-resistant mutation of Escherichia coli by carcinogenic agents

Thesis, University of Kentucky, 1949

\* The effect of 9:10-bishydroxymethyl-1:2-benzanthracene and alpha-naphthalene acetic acid on the cell-division mechanism of Saccharomyces cerevisiae

Genetics, 35:690, 1959 (abstract)

A clinical, pathological, and mycological study of fatal case of histoplasmosis in an infant

Mycopathologia et Mycologia Applicata, 6:86-91, 1951  
With J.T. McClellan and Margaret Hotchkiss

\*Effect of gonadotrophic hormones on systemic moniliasis in mice

Bact. Proceedings, 113, 1951 (abstract)

With R.H. Weaver

An investigation of the therapy of systemic moniliasis in mice ensuing from studies of the dimorphism mechanism in yeasts

Dissertation, University of Kentucky, 1951

\*Enhancement of systemic moniliasis in mice by injection of yeast cells

Bact. Proceedings, 113, 1951 (abstract)

With R.H. Weaver

A nephelometric technique for large cultures

Mycologia, 44:575-577, 1952

\*A natural mineral medium for the isolation of certain fungi

Bact. Proceedings, 56, 1952 (abstract)

Studies of the dimorphism mechanism in Saccharomyces cerevisiae

Mycopathologia et Mycologia Applicata, 6:182-230, 1952

The effect of environmental temperature on cortisone toxicity for mice

Science, 116:685, 1952

The dimorphism phenomenon in yeasts

Bact. Reviews, 17:51-92, 1953

With R.H. Weaver

The effect of environmental temperature on the course of systemic moniliasis in mice  
Mycologia, 45:359-363, 1953

The susceptibility of mice infected with Cryptococcus neoformans encephalomyocarditis (EMC) virus  
J. Bact., 65:480-481, 1953

The enhanced dissemination of moniliasis in mice by the injection of yeast cells  
J. Creighton Univ. School of Med., 8:20-24, 1953

\*The effect of cortisone and somatotrophic hormone (STH) on systemic moniliasis in mice  
Proc. Nebraska Acad. Sci., 7. 1953 (abstract)

The use of yeast cells to enhance the virulence of Candida albicans  
Mycopathologia et Mycologia Applicata, 6:260-289, 1953

\*The effect of cortisone on the course of systemic monillasis in mice  
1. The efficacious effect of cortisone for severe infections  
Ibid, 6:325-336, 1953  
  
11. An attempt to reverse the toxic affect of cortisone with lowered environmental temperature or somatotrophic hormone (STH)  
Ibid, 6:337-353, 1953

Experimental studies on the pathogenesis of encephalomyocarditis (EMC) virus for mice. 1. The factor of sex of animal as affecting pathogenicity of inoculum and susceptibility to infection  
J. Bact., 66:105-111, 1953

An automatic inoculating instrument  
Laboratory Practice, 2:658-659, 1953

Effect of corisone on the course of systemic moniliasis in mice an influence by the severity of infection  
Bact. Proceedings, 72, 1953 (abstract)

The factor of sex in thepathogenesis of encephalomyocarditis (EMC) virus for mice  
Riassunti delle Comunicazioni, VI Congresso Internazionale di Microbiologia, 11, 102, 1953  
Atti del VI Congresso Internazionale di Microbiologia, Roma, Vol. 3, Sez. VIII, pp189-194

The effect of cortisone and somatotrophic hormone on the course of systemic moniliasis in mice  
Riassunti delle Comunicazioni, VI Congresso Internazionale di Microbiologia, 111, 44, 1953

The laboratory diagnosis of mycotic infections. 1. Histoplasmosis  
Nebraska State Med. J., 39:339-341, 1954

Paper and Publication (cont'd.)

11. Moniliiasis  
Ibid., 39:343-346, 1954

The mutagenicity of some carcinogenic compounds for Escherichia coli  
Genetics, 39:141-149, 1954  
With M. Fishman and R.H. Weaver

The effect of cortisone and somatotrophic hormone on vaccinia  
virus lesions and bensyl alcohol toxicity in the embryonated egg  
J. Infectious Diseases, 95:160-164, 1954  
With J. M. Severens. P. Jurtshuk, jr., and C.L. Wittenberger

A new type of paper impregnated disc for determining microbial  
sensitivity to antibiotics and other chemotherapeutic agents  
Antibiotics and Chemotherapy, 4:1007-1010, 1954

The therapeutic affect of cortisone, somatotrophic hormone, and  
hesperedin methyl chalcone in suppressing experimental moniliiasis  
in mice

Mycologia, 47:305-310, 1955

\* The reduction of the number and size of vaccinia lesions in  
embryonated eggs treated with cortisone and somatotrophic hormone  
Bact. Proceedings, M 54, 1954 (abstract)  
With J. M. Severens, C.L. Wittenberger, and P. Jurtshuk, Jr.

\* The influence of sex hormones, cortisone, and somatotrophin hormone  
on systemic moniliiasis in mice  
Bact. Proceedings, 86, 1954 (abstract)

\* The effect of cortisone, somatotrophin, and vitamin P on moniliiasis  
Prod. Nebraska Acad. Sciences, 9, 1954 (abstract)

The therapeutic effectiveness of piromen for experimental moniliiasis  
American Inst. of Biological Sci., Bulletin, 59, 1954

A Multi-tipped disc for determining microbial sensitivity to  
antibiotics and other chemotherapeutic agents  
American Inst. of Biological Sci., Bulletin, 63, 1954

The effect of hormones on experimental moniliiasis in mice. 1. Sex  
hormones, cortisone, and somatotrophin  
Mycopathologia, 8:62-72, 1957

11. Gonadotrophins  
Ibid 1, 77-82

Studies on the dimorphism of histoplasma capsulatum 1. The roles  
of -SH groups and incubation temperature  
Experimental Cell Research, 12:92-107, 1957

The therapeutic effectiveness of fungistatic powder for tinea pedis  
Illinois Medical J., 112-, 1957

Papers and Publications (con'd)

A new agar for in vitro anti-microbial sensitivity testing  
Antibiotics and Chemotherapy, 8:559-606, 1958  
With R. M. Bechtle

Induced dimorphism in pathogenic fungi  
X Int. congress genetics, Proc, vol II  
With J. W. Rippon

The influence of hormones on experimental moniliasis  
Monographs on therapy, Squibb Inst. Med. Res., 2:80-82, 1957

Induced dimorphism in dermatophytes  
Mycologia, 51:902-914, 1959  
With J. W. Rippon

The role of SH-containing compounds in inhibiting the growth of  
dimorphic pathogenic fungi  
VII International Congress of Microbiology, Stockholm,  
April 8, 1958  
With V. F. Gerencser

Experimental Histoplasmosis in Cold Blooded Animals  
59th Gen. Meeting of S.A.B. St. Louis, Missouri, May 10-16, 1959  
With J. W. Rippon

Induced Pathogenicity of Dermatophytes for Deep Organs of Experimental  
Animals  
59th Gen. Meeting of S.A.B. St. Louis, Missouri, May 10-16, 1959  
With J. W. Rippon

Experimental Histoplasmosis in Cold-blooded Animals  
Mycopathologia, 11:241-249, 1959  
With J. W. Rippon

Studies on Synergists for Antimicrobial Agents  
Antibiotics Annual, Medical Encyclopedia, Inc., New York, N. Y.  
855-864, 1958-59  
With R. M. Bechtle

Studies on Synergists for Antimicrobial Agents. III. Compounds  
having plant growth activity  
Antibiotics Annual, Medical Encyclopedia, Inc., N. Y.  
316-320, 1959-1960

The Potentiation of Antibiotics in the Treatment of Experimental  
Infections  
Ibid., 321-325, 1959-1960

Studies on Synergists for Antimicrobial Agents. II. Anti-Mycebacterial  
agents  
Antibiotics and Chemotherapy, 9:715-725, 1959  
With R. M. Bechtle

Papers and Publications (cont'd.)

Cellulose acetate electrophoresis in Microbiology and Immunology  
Tr. N.Y. Acad. of Sci., 23: 519-530, April, 1961

Use of cellulose acetate strips for electrophoresis if amino acids  
Analytical Chem. 34: 777, June, 1962

The Directed isolation of mutants producing increased amounts of  
metabolites  
Journ. of Applied Bact., 25: 187-194, August, 1962  
With M.E. Rafelson (Jr.)

Comparative studies with a new isolation medium for Candida albicans.  
Bact. Proceedings, Amer. Soc. for Microbiology, 1962  
With M. Goldin

\*A new alginic adjuvant - physical and chemical properties  
Bact. Proceedings, Amer. Soc. for Microbiology, 1962

Irreproducible Research  
IEEE Transactions on Professional Communication,  
Vol. PC-16, No. 3, Sept., 1973

Hemagglutination Inhibition Assay for Gentamicin  
Antimicrobial Agents and Chemotherapy, 11/2: 359-361, Feb., 1977

Preparation of a Biologically Stable and Immunogenically Competent  
Astatinated Protein  
Int. Journ. of Nuclear Med. and Biology, Vol. 4: 219-224, 1977

Hemagglutination Inhibition (chapter of book) Guidelines for Analytical  
Toxicology Programs. CRC Press, Inc. Vol. II, 225-233, 1977

\*Diagnostic Procedures in Systemic Mycotic Disease  
Sixth Annual Post-Graduate Course in Med. Tech.  
Royal Inland Hospital, Kamloops, B.C., 1963

Drug Monitoring and Pharmacokinetic Data  
With: H.C. Pribor and G. Morrell, Pathotox Pub. 1980

Saccharin - A Report by M.F. Cranmer  
Edited, Pathotox Publishers, 1980

A Diagnostic Test for the Dog Heartworm, *Dirofilaria Immitis*  
Veterinary and Human Toxicology, Vol. 24, No. 1, February 1982, pp. 1-7

How Many Humans Have Canine Heartworm?  
Diagnostic Medicine, May/June 1983  
With: Barry A. Scherr, M.D.

Papers and Publications (cont'd.)

Advances in Human Nutrition - Volume 2  
With: Edward J. Calabrese, M.D.  
Chem-Orbital Publisher, 1985

Advances in Human Nutrition - Volume 3  
With: Jon J. Kabara, M.D.  
Chem-Orbital Publisher, 1986

Health Effects of Asbestos: Volumes I, II, III  
With: Premysl V. Pelnar, M.D.  
Chem-Orbital Publisher, 1988

Microbial Cell Division Mechanisms and Related Antibiosis  
In: Essays in Microbiology, Ed: Albert Balows,  
University of Kentucky Press

Selected Papers From The Journal of Irreproducible Results, 3rd Edition  
Edited: George H. Scherr, Ph.D.  
Marboro Books Corporation, 1981

The Best of The Journal of Irreproducible Results  
Edited: George H. Scherr, Ph.D.  
Workman Publishing Company, 1983

Journal Der Unwiederholbaren Experimente  
Edited: Dr. George H. Scherr and  
Richard Liebmann-Smith  
Wolfgang Kruger Verlag, 1983

Journal Der Unwiederholbaren Experimente II  
Edited: Dr. George H. Scherr and  
Gabriele Herbst,  
Barbara Keller,  
Heidi Rei  
Ernst Guggolz  
Wolfgang Kruger Verlag, 1986

Alginates and Alginate Fibers in Clinical Practice  
Wounds, Vol 4: 74-80 , 1992

Selected Papers From The Journal of Irreproducible Results  
Edited: George H. Scherr and  
Jim Glenn  
Published by Barnes and Noble, 1997

---

\*Papers presented at international meetings.

Research  
Grants-in-aid

Office of Naval Research, Department of the Navy  
The effect of Hormones on Experimental Moniliasis  
1952-1953  
1953-1954 (renewed)

American Academy of Arts and Sciences  
The effect of Hormones on Experimental Histoplasmosis  
1952-1953

Wyeth Laboratories  
Clinical Evaluation of Therapeutic Measures for Dermatophytosis  
In collaboration with Dr. Zeno Korth  
1952-1953  
1953-1954 (renewed)

Wallace and Tiernan  
Clinical evaluation of Therapeutic measures for Dermatophytosis  
In collaboration with Dr. Z. Korth  
1952-1953

American Medical Association  
Effect of Hormones on Experimental Histoplasmosis  
1952-1953

Investigation of dimorphism in pathogenic fungi  
University of Illinois, Graduate Research  
1954-1955  
1956-1957 (renewed)

N.I.H. (National Institute of Health)  
Studies on Dimorphism  
1957-1958  
1958-1959 (renewed)

Baxter Laboratories  
Studies on Chemotherapy  
1957-1958  
1958-1959 (renewed)

Cook County Tuberculosis Society  
Studies on Chemotherapy of Tuberculosis in mice  
1959-1960

American Cancer Society Institutional Grant  
Studies on cell division and growth  
1958-1959  
1959-1960 (renewed)

## Societies

### Past Membership

Genetics Society of America  
Society for Industrial Microbiology  
Mycological Society of America  
International Society for Medical and Veterinary Mycology

### Current Membership

Sigma Xi  
American Association for the Advancement of Science  
Society of American Bacteriologists  
New York Academy of Sciences  
International Society for Environmental Toxicology and Cancer

### Societies - Position Held

Chicago Medical Mycological Society - Past President  
Society Industrial Microbiology, Chicago Section - Past Vice-President  
American College of Toxicology - Past Secretary

### Committees

Chairman  
Member  
Member

### University of Illinois - (1954-1959)

Fellowship Fund Search Committee  
Executive Committee of the Graduate Faculty  
Committee on Medical Education  
for National Defense

### Councilor

### International Society for Environmental Toxicology and Cancer

### Editor

Mycopathologia et Mycologia Applicata  
(1953 - 1957)  
Journal of Environmental Pathology  
and Toxicology  
Journal of Irreproducible Results  
Journal of Environmental Pathology,  
Toxicology and Oncology

### Publisher

Journal of Environmental Pathology  
and Toxicology  
Neurotoxicology  
Journal of Irreproducible Results  
Journal of Environmental Pathology,  
Toxicology and Oncology

### Civic

Rotary - Chicago Heights, IL (1955 - 1962)  
Park Forest Health Council, Park Forest, Illinois  
Member 1955 - 1963

Chairman of the Committee on Chronic Disease Control  
Chairman of the Committee on Community Health Planning & Education

PATENTS - GEORGE H. SCHERR

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
1,021,721	Great Britain			Directed Isolation of Mutants
17,969	Israel			Directed Isolation of Mutants
434,569	Switzerland			Directed Isolation of Mutants
3,071,518	USA	1/1/63		Directed Isolation of Mutants
28,197	Great Britain			Specimen & Culture Tube Device
719,959	USA			Specimen & Culture Tube Device
312,937	Sweden	11/6/69	Consolidated Labs	Ovulation Testing
328,718	Sweden	1/7/71	G. H. Scherr	Ovulation Testing
3,436,186	USA	4/1/69	Consolidated Labs	Assessing Ovulation Function
45-28276	Japan			Ovulation
85,507	Mexico	2/16/65	Colab	Ovulation Function
752,975	Italy	3/1/67	Colab	Ovulation
1,431,133	France	1/31/66	Consolidated Labs	Ovulation
1,424,948	France	12/6/65	Colab	Ovulation
454-496	Switzerland	2/16/65	Colab	Ovulation
4,781	Philippines	1/12/70	Colab	Ovulation
140,822	New Zealand	2/17/65	Colab	Ovulation
22,984	Israel	4/30/69	Colab	Ovulation
17,353	Columbia	10/7/69	Colab	Ovulation
22,983	Israel	4/30/69	Colab	Ovulation
140,823	New Zealand	2/17/65	Colab	Ovulation
140,821	New Zealand	2/17/65	Consolidated Labs	Ovulation
28,815	Ireland	2/19/65	G. H. Scherr	Ovulation

**PATENTS (CONT'D)**

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
461-140	Switzerland	2/16/65	Colab	Ovulation
28,775	Ireland	2/19/65	G. H. Scherr	Ovulation
312,017	Sweden	10/9/69	Colab	Ovulation
15,778	Venezuela	1/4/66	Colab	Ovulation
16,040	Venezuela	4/25/66	Colab	Ovulation
798,245	Canada			Estrindex
798,246	Canada			Estrindex
3,561M	France	10/18/62	Consolidated Labs	New Composition of Vaccines & Antigens
1,505,310	France	10/18/62	Consolidated Labs	Fabrication of New Compositions for Antigens
328,369	Sweden	12/31/70	Consolidated Labs	Fabrication of New Compositions for Antigens
150,892	USA	11/8/61		Parenteral Vaccine & Antigen Composition
3049-P	Argentina			Alginate Vaccine Adjuvant
262,763	Australia			Alginate Vaccine Adjuvant
498,644	Belgium			Alginate Vaccine Adjuvant
737,081	Canada			Alginate Vaccine Adjuvant
103,795	Denmark			Alginate Vaccine Adjuvant
1,170,582	Germany	12/3/64	Consolidated Labs	Alginate Vaccine Adjuvant
950,498	Great Britain			Alginate Vaccine Adjuvant
79,822	India			Alginate Vaccine Adjuvant
18,006	Israel			Alginate Vaccine Adjuvant
470,184	Switzerland			Alginate Vaccine Adjuvant
3,075,883	USA			Alginate Vaccine Adjuvant

**PATENTS (CONT'D)**

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
2,787,581	USA	4/2/57	G.H. Scherr	Means for Assessing Growth of Microorganisms
2,701,229	USA	2/1/55	G.H. Scherr	Apparatus for Cultivation of Microorganisms
578,055	Canada	6/23/59	G.H. Scherr	Effect of Agents on Growth of Microorganisms
1,171,501	France	10/6/58		Effect of Agents on Growth of Microorganisms
90,498	Denmark	2/12/57		Effect of Agents on Growth of Microorganisms
774,155	Great Britain	5/8/57		Activity of Chemical Compounds/ Microorganisms
2,744,648	USA	5/8/56	G.H. Scherr	Closure (Automatic Inoculating Instrument)
214,180	USA	8/2/62		Culture Medium - Candida Albicans
4,100,268	USA	7/11/78	G.H. Scherr	Detection of Gentamicin
4,096,138	USA	6/20/78	G.H. Scherr	Immunological Test Procedure
3,913,487	USA	10/21/75	G.H. Scherr	Projectile
	USA			Distemper Diagnostic Antigen
1,234,417	United Kingdom	8/15/68	Colab	Electrophoresis Device
695,931	USA			Electrophoresis Device
61,089	Brazil			Multidisk (Sensitivity Testing)
578,055	Canada			Multidisk (Sensitivity Testing)
90,498	Denmark			Multidisk (Sensitivity Testing)
1,171,501	France			Multidisk (Sensitivity Testing)
774,155	Great Britain			Multidisk (Sensitivity Testing)
2,787,581	USA			Multidisk (Sensitivity Testing)
688,595	Canada	6/16/64	G.H. Scherr	Potentiation of Antibiotics

**PATENTS (CONT'D)**

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
35,299/60	England			Potentiation of Antibiotics
3,251,738	USA	5/17/66	G.H. Scherr	Potentiation of Antibiotics
1,513,648	England	6/7/78	G.H. Scherr	Detection of Gentamicin
4,189,466	U. S. A.	2/19/80	G.H. Scherr	Protein A Conjugates
17,036	Columbia	6/3/71	G. H. Scherr	Ovulation
15,901	Columbia	9/27/67	Consolidated Labs	Ovulation Function
727,081	Canada	2/1/66	Consolidated Labs	Parenteral Vaccine & Antigen Composition
659,988	Belgium	2/19/65	Colab	Estrindex
659,987	Belgium	2/19/65	Consolidated Labs	Estrindex
659,989	Belgium	2/19/65	Colab	Estrindex
4,761,281	U.S.A.	8/2/88	G.H. Scherr	Vaccine From Dirofilaria Extracts
5,674,524	U.S.A.	10,07,97	G. H. Scherr	Alginate Fibrous Dressings and Method of Making
5,718,916	U.S.A.	2/17/98	G. H. Scherr	Alginate Foam Products
09/676/670 (App1.)	U.S.A.	filed 4/29/99 Pending	G. H. Scherr	Alginate Foam Compositions
US02/23561	P.C.T.	filed 7/22/02 Pending	G.H. Scherr	Silver Alginate Foam Compositions
09/818928 (App1.)	U.S.A.	filed 8/28/01 Pending	G. H. Scherr	Cellulosic Foam Compositions
US03/04992 (App1.)	P.C.T.	filed 2/18/03 Pending	G.H. Scherr	Alginate Foam Compositions
09/912,337 (App1.)		7/26/01 accepted to issue	G.H. Scherr	Silver Alginate Foam Compositions

TRADEMARKS - GEORGE H. SCHERR

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Trademark</u>
795,428	USA	9/7/68	Colab	Estrindex
947,620	USA	11/21/72	Blackwell Publications	The Journal of Irreproducible Results
947,621	USA	11/21/72	Blackwell Publications	JIR
144,448	Canada	3/18/66	Consolidated Labs (Canada) Ltd.	Algivant
1,111	Denmark	10/1/70	G. H. Scherr	Estrindex
204,632	Italy	3/12/65	Colab	Estrindex
119,314	Sweden	4/7/67	Colab	Estrindex
12,824	Philippines	5/11/67	Colab	Estrindex
466,904	Spain	2/22/65	Colab	Estrindex
148,148	Canada	11/18/66	Consolidated Labs (Canada) Ltd.	Estrindex
77,569	New Zealand	1/6/65	Colab	Estrindex
151,348	Chili	9/17/65	Colab	Estrindex
54,192	Venezuela	6/5/68	Colab	Estrindex
613,716	USA	10/11/55		Multidisk
717,052	USA	6/20/61		Colab and Design
717,053	USA	6/20/61		Colab
708,611	USA	12/20/60		Fibros
879-880	Ecuador	6/29/66	G. H. Scherr	Multidisk
62,312	Columbia	9/12/66	G. H. Scherr	Multidisk
154,401	Chile	6/20/66	G. H. Scherr	Multidisk
6,699,748	El Salvador	12/7/66	G. H. Scherr	Multidisk
876,984	USA	9/16/69	Colab	Monostat

TRADEMARKS (CONT'D)

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Trademark</u>
715,160	USA	5/9/61	Consolidated Labs	Calgiswab
75,347	New Zealand	3/9/64	Consolidated Labs	Calgiswab
203,974	Italy	4/5/67	Colab	Calgiswab
	France		Consolidated Labs	Calgiswab
A186,380	Australia	7/6/66	Consolidated Labs	Calgiswab
811,618	USA	7/26/66	Colab	Algivant
902,901	Great Britain	12/13/66	Colab	Algivant
A206,801	Australia	12/12/66	Colab	Algivant
68,067	Ireland	1/6/65	Colab	Estrindex
54,870	Austria	7/1/65	Colab	Estrindex

PRODUCT RESEARCHPRODUCT  
MARKETED

Auxotab - entero-identification	Yes
Ovulation Test	Yes
Identification plate for Candida	Yes
Antibiotic Assay Medium	Yes
Blood Agar Base No. 2	Yes
Diagnostic Sensitivity Test Agar Base	Yes
Microbial Transport Media	Yes
1. Modified Stuart's Transport Medium	Yes
2. Urine Transport Medium	Yes
3. Fluid Transport Medium	Yes
4. Viral Transport Medium	Yes
5. Trichomonas Transport & Culture Medium	Yes
Lowenstein-Jensen media	Yes
Dermatophyte Medium	Yes
Acryl Particles	Yes
Dental Calcium Alginate Wool	Yes
Histoplasmosis Latex Antigen	Yes
Rheumatoid Arthritis Latex antigen	Yes
Alginate adjuvant	Yes
Alginate Wool	Yes
Alginate swabs	Yes
Calcium alginate swab in tube	Yes
Infectious Mononucleosis antigen	Yes
Histoplasmosis Latex test	Yes
Polystyrene Latex Particles	Yes
Streptococcus MG agglutination test	Yes
Urethro-genital Calgiswab	Yes
Multidisk sensitivity disk	Yes
Test for Cystic Fibrosis	Yes

### PRODUCT RESEARCH (CONT'D)

#### PRODUCT MARKETED

Cellulose acetate electrophoresis	Yes
Immuno-diffusion agars	Yes
Cell Press for disrupting microorganisms and tissue cells	Yes
Bacterial sensitivity teaching kit for high schools	Yes
Thin Layer chromatography teaching kit	Yes
Testing for Drugs of Abuse	Yes
Gentamicin detection by H I	No
D. imitis (dog heartworm) diagnostic	Yes
Alginate surgical hemostat	No
Dental hemostat	No
Laser nephelometry reagents	No
Malaria diagnostic	No
Pregnancy test	No
Calcium alginate fiber dressings	Yes
Calcium alginate foam dressings	Yes
Silver alginate foam dressings	Yes